Intracellular Cargo Delivery Using Tat Peptide and Derivatives

Medicinal Research Reviews

Volumn 24, Issue 1, 2004, Pages 1-12

  Zhao, Ming ^a   Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cell permeable peptides; Tat peptide; Transduction

Indexed keywords

CASPASE 3; CRE RECOMBINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOSPORIN A; DIAGNOSTIC AGENT; HYBRID PROTEIN; NUCLEIC ACID; PEPTIDE DERIVATIVE; PROTEIN BCL XL; RHO FACTOR; TRANSACTIVATOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

CELL MEMBRANE TRANSPORT; DRUG DELIVERY SYSTEM; HIGH THROUGHPUT SCREENING; MACROMOLECULE; MEMBRANE PERMEABILITY; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE H RAS; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEMS; GENE PRODUCTS, TAT; HUMANS; NUCLEIC ACIDS; PEPTIDE FRAGMENTS; PROTEIN TRANSPORT;

EID: 0347511729     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10056     Document Type: Review

References (83)

1. Lindsay MA. Peptide-mediated cell delivery: Application in protein target validation. Curr Opin Pharmacol 2002;2:587-594.
2. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994;269:10444-10450.
3. Pooga M, Hallbrink M, Zorko M, Langel U. Cell penetration by transportan. FASEB J 1998;12:67-77.
4. Soomets U, Lindgren M, Gallet X, Hallbrink M, Elmquist A, Balaspiri L, Zorko M, Pooga M, Brasseur R, Langel U. Deletion analogues of transportan. Biochim Biophys Acta 2000;1467:165-176.
5. Bennett RP, Dalby B, Guy PM. Protein delivery using VP22. Nat Biotechnol 2002;20:20.
6. Langel U. Cell-pepetrating peptides: Processes and applications. London, UK: CRC Press; 2002.
7. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;276:5836-5840.
8. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55:1189-1193.
9. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;91:664-668.
10. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002;277:2437-2443.
11. Silhol M, Tyagi M, Giacca M, Lebleu B, Vives E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur J Biochem 2002; 269:494-501.
12. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-590.
13. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc Natl Acad Sci USA 2000;97:13003-13008.
14. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL, Wender PA. Arginine-rich molecular transporters for drug delivery: Role of backbone spacing in cellular uptake. J Med Chem 2002;45:3612-3618.
15. Wender PA, Rothbard JB, Jessop TC, Kreider EL, Wylie BL. Oligocarbamate molecular transporters: Design, synthesis, and biological evaluation of a new class of transporters for drug delivery. J Am Chem Soc 2002;124:13382-13383.
16. Tung CH, Mueller S, Weissleder R. Novel branching membrane translocational peptide as gene delivery vector. Bioorg Med Chem 2002;10:3609-3614.
17. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 2001;1515:101-109.
18. Rusnati M, Tulipano G, Urbinati C, Tanghetti E, Giuliani R, Giacca M, Ciomei M, Corallini A, Presta M. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J Biol Chem 1998;273:16027-16037.
19. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001;276:3254-3261.
20. Violini S, Sharma V, Prior JL, Dyszlewski M, Piwnica-Worms D. Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: Lack of correlation with heparan sulfate. Biochemistry 2002;41:12652-12661.
21. Prochiantz A. Messenger proteins: Homeoproteins, TAT, and others. Curr Opin Cell Biol 2000;12:400-406.
22. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: Unrestricted delivery into all cells? Trends Cell Biol 2000;10:290-295.
23. Lundberg M, Johansson M. Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun 2002;291:367-371.
24. Snyder EL, Dowdy SF. Protein/peptide transduction domains: Potential to deliver large DNA molecules into cells. Curr Opin Mol Ther 2001;3:147-152.
25. Palmeri D, Malim MH. Importin beta can mediate the nuclear import of an arginine-rich nuclear localization signal in the absence of importin alpha. Mol Cell Biol 1999;19:1218-1225.
26. Gorlich D, Mattaj IW. Nucleocytoplasmic transport. Science 1996;271:1513-1518.
27. Truant R, Cullen BR. The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. Mol Cell Biol 1999;19:1210-1217.
28. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999;285:1569-1572.
29. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 1999;10:186-191.
30. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-16017.
31. Bonifaci N, Sitia R, Rubartelli A. Nuclear translocation of an exogenous fusion protein containing HIV Tat requires unfolding. AIDS 1995;9:995-1000.
32. Bergemann AD, Ma ZW, Johnson EM. Sequence of cDNA comprising the human pur gene and sequence-specific single-stranded-DNA-binding properties of the encoded protein. Mol Cell Biol 1992;12:5673-5682.
33. Darbinian N, Gallia GL, King J, Del Valle L, Johnson EM, Khalili K. Growth inhibition of glioblastoma cells by human Pur(alpha). J Cell Physiol 2001;189:334-340.
34. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG, Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96:4325-4329.
35. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 1995;83:1149-1158.
36. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG, Jr. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 1996;16:6623-6633.
37. Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N, Helin K. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 1993;13:7813-7825.
38. Watanabe N, Kato T, Fujita A, Ishizaki T, Narumiya S. Cooperation between mDia1 and ROCK in Rho-induced actin reorganization. Nat Cell Biol 1999;1:136-143.
39. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279(5350):509-514.
40. Chellaiah MA, Soga N, Swanson S, McAllister S, Alvarez U, Wang D, Dowdy SF, Hruska KA. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem 2000;275: 11993-12002.
41. Paterson HF, Self AJ, Garrett MD, Just I, Aktories K, Hall A. Microinjection of recombinant p21rho induces rapid changes in cell morphology. J Cell Biol 1990;111:1001-1007.
42. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992;70:401-410.
43. Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol 1995;15:1110-1122.
44. Kondo K, Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117-125.
45. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003;13:83-89.
46. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002;13:29-37.
47. Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis. Adv Exp Med Biol 2001;502:365-376.
48. Willam C, Masson N, Tian YM, Mahmood SA, Wilson MI, Bicknell R, Eckardt KU, Maxwell PH, Ratcliffe PJ, Pugh CW. Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. Proc Natl Acad Sci USA 2002;99:10423-10428.
49. Gorospe M, Egan JM, Zbar B, Lerman M, Geil L, Kuzmin I, Holbrook NJ. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol 1999; 19:1289-1300.
50. Zbar B. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv 1995;25:219-232.
51. Gnarra JR, Lerman MI, Zbar B, Linehan WM. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995;22:3-8.
52. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 2001;61:1768-1775.
53. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 2000;275:20700-20706.
54. Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 2002;62: 2013-2018.
55. Chen M, Won DJ, Krajewski S, Gottlieb RA. Calpain and mitochondria in ischemia/reperfusion injury. J Biol Chem 2002;277:29181-29186.
56. Salvemini D, Cuzzocrea S. Superoxide, superoxide dismutase, and ischemic injury. Curr Opin Investig Drugs 2002;3:886-895.
57. Stohs SJ. The role of free radicals in toxicity and disease. J Basic Clin Physiol Pharmacol 1995;6:205-228.
58. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 1990;186:1-85.
59. Jin LH, Bahn JH, Eum WS, Kwon HY, Jang SH, Han KH, Kang TC, Won MH, Kang JH, Cho SW, Park J, Choi SY. Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. Free Radic Biol Med 2001;31:1509-1519.
60. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-273.
61. Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 2002;168:2393-2401.
62. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang RF. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002;109:1463-1470.
63. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999;5:29-33.
64. Sandgren S, Cheng F, Belting M. Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans. J Biol Chem 2002;277:38877-38883.
65. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res 2002;19:744-754.
66. Polyakov V, Sharma V, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D. Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy. Bioconjug Chem 2000;11:762-771.
67. Bullok KE, Dyszlewski M, Prior JL, Pica CM, Sharma V, Piwnica-Worms D. Characterization of novel histidine-tagged tat-peptide complexes dual-labeled with (99m)tc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy. Bioconjug Chem 2002;13:1226-1237.
68. Bhorade R, Weissleder R, Nakakoshi T, Moore A, Tung CH. Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-tat derived membrane translocation peptide. Bioconjug Chem 2000;11:301-305.
69. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 2000;6:1253-1257.
70. Nori A, Jensen KD, Tijerina M, Kopecková P, Kopecek J. Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug Chem 2003;14:44-50.
71. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001;98:8786-8791.
72. Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: A kinetic and efficacy study. Mol Pharmacol 2002;62:864-872.
73. Eguchi A, Akuta T, Okuyama H, Senda T, Yokoi H, Inokuchi H, Fujita S, Hayakawa T, Takeda K, Hasegawa M, Nakanishi M. Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J Biol Chem 2001;276:26204-26210.
74. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000;18: 410-414.
75. Wunderbaldinger P, Josephson L, Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 2002;13:264-268.
76. Zhao M, Kircher MF, Josephson L, Weissleder R. Differential conjugation of tat peptide to super-paramagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 2002;13:840-844.
77. Matsushita M, Tomizawa K, Moriwaki A, Li ST, Terada H, Matsui H. A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J Neurosci 2001;21: 6000-6007.
78. Myou S, Zhu X, Boetticher E, Myo S, Meliton A, Lambertino A, Munoz NM, Leff AR. Blockade of focal clustering and active conformation in beta 2-integrin-mediated adhesion of eosinophils to intercellular adhesion molecule-1 caused by transduction of HIV TAT-dominant negative Ras. J Immunol 2002;169: 2670-2676.
79. Corradin S, Ransijn A, Corradin G, Bouvier J, Delgado MB, Fernandez-Carneado J, Mottram JC, Vergeres G, Mauel J. Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein. Biochem J 2002;367:761-769.
80. Fujiwara T, Yamamori T, Akagawa K. Suppression of transmitter release by Tat HPC-1/syntaxin 1A fusion protein. Biochim Biophys Acta 2001;1539:225-232.
81. Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F. Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: A tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci USA 2002;99:4489-4494.
82. He DY, Vagts AJ, Yaka R, Ron D. Ethanol induces gene expression via nuclear compartmentalization of receptor for activated C kinase 1. Mol Pharmacol 2002;62:272-280.
83. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001;88:1102-1104.